Roobol M - Search Results

1

Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future.

Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Van Poppel H, et al. Among authors: roobol m. Nat Rev Urol. 2022 Sep;19(9):562-572. doi: 10.1038/s41585-022-00638-6. Epub 2022 Aug 16. Nat Rev Urol. 2022. PMID: 35974245 Review.

2

Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).

Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Vis AN, et al. Among authors: roobol m. Prostate. 2001 Jun 1;47(4):252-61. doi: 10.1002/pros.1069. Prostate. 2001. PMID: 11398172 Clinical Trial.

3

Pathologic features of prostate cancer found at population-based screening with a four-year interval.

Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schröder FH. Hoedemaeker RF, et al. Among authors: roobol m. J Natl Cancer Inst. 2001 Aug 1;93(15):1153-8. doi: 10.1093/jnci/93.15.1153. J Natl Cancer Inst. 2001. PMID: 11481387 Free article. Clinical Trial.

4

A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate.

Roobol MJ, Kranse R, van der Cruijsen IW, Schröder FH. Roobol MJ, et al. Urology. 2002 Jan;59(1):91-6. doi: 10.1016/s0090-4295(01)01479-0. Urology. 2002. PMID: 11796288 Clinical Trial.

5

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Raaijmakers R, et al. Urology. 2002 Nov;60(5):826-30. doi: 10.1016/s0090-4295(02)01958-1. Urology. 2002. PMID: 12429309

6

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

Roobol MJ, Kranse R, de Koning HJ, Schröder FH. Roobol MJ, et al. Urology. 2004 Feb;63(2):309-13; discussion 313-5. doi: 10.1016/j.urology.2003.09.083. Urology. 2004. PMID: 14972478

7

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH. Raaijmakers R, et al. Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028. Urology. 2004. PMID: 14972481

8

Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.

Postma R, Roobol M, Schröder FH, van der Kwast TH. Postma R, et al. Among authors: roobol m. Cancer. 2004 Mar 1;100(5):968-75. doi: 10.1002/cncr.20048. Cancer. 2004. PMID: 14983492 Free article. Clinical Trial.

9

Consistency of prostate cancer grading results in screened populations across Europe.

Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Määtänen L, Pihl CG, Santonja C, Bubendorf L, Neetens I, Di Lollo S, Hoedemaeker RF. Van der Kwast TH, et al. Among authors: roobol mj. BJU Int. 2003 Dec;92 Suppl 2:88-91. doi: 10.1111/j.1465-5101.2003.04405.x. BJU Int. 2003. PMID: 14986593 Clinical Trial.

10

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.

Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schröder FH. Raaijmakers R, et al. J Urol. 2004 Jun;171(6 Pt 1):2245-9. doi: 10.1097/01.ju.0000127731.56103.50. J Urol. 2004. PMID: 15126795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

486 results

Search Page